Table 1.
Baseline characteristics of the study group
| Control group (n = 25) | Study group (n = 90) | p value | |
|---|---|---|---|
| Age, years | 55±13 | 60±14 | 0.09 |
| Male gender | 12 (48) | 47 (52) | 0.56 |
| BMI | 26±4 | 27±7 | 0.42 |
| eGFR, mL/min/1.73 m2 | 84 (75 to 94) | 42 (30 to 58) | 0.001* |
| LDL, mg/dL | 114±22 | 99±40 | 0.02 |
| HDL, mg/dL | 63 (51 to 78) | 57 (46 to 73) | 0.22 |
| TG, mg/dL | 93 (66 to 133) | 133 (96 to 183) | 0.005* |
| TC, mg/dL | 200±22 | 181±40 | 0.02 |
| CRP, mg/dL | 1.1 (0.6 to 1.8) | 1.4 (0.7 to 3.0) | 0.14 |
| Fasting glucose, mg/dL | 92 (84 to 98) | 98 (89 to 107) | 0.04 |
| WBC, G/L | 5.64 (5.33 to 6.50) | 7.3 (5.8 to 8.8) | 0.002* |
| Neutrophils, G/L | 3.17 (2.91 to 3.98) | 4.3 (3.7 to 5.7) | 0.002* |
| Lymphocytes, G/L | 1.73 (1.44 to 2.02) | 1.9 (1.5 to 2.5) | 0.26 |
| NtoL | 1.90 (1.57 to 2.61) | 2.2 (1.6 to 3.2) | 0.20 |
| Platelets, G/L | 243 (219 to 254) | 224 (189 to 250) | 0.13 |
| Sodium, mmol/L | 141 (140 to 142) | 141 (139 to 143) | 0.78 |
| Potassium, mmol/L | 4.20 (4.00 to 4.40) | 4.6 (4.4 to 4.9) | 0.001* |
| CXCL12, ng/mL | 2.39 (2.09 to 2.54) | 2.79 (2.51 to 3.14) | 0.001* |
| Clinic SBP, mm Hg | 120 (112 to 124) | 129 (120 to 138) | 0.001* |
| Clinic DBP, mm Hg | 75 (70 to 81.5) | 80 (70 to 85) | 0.35 |
| 24-h SBP, mm Hg | 118 (112 to 125) | 126 (118 to 135) | 0.008* |
| 24-h DBP, mm Hg | 75 (70 to 82) | 74 (66 to 79) | 0.88 |
| Day SBP, mm Hg | 120±9 | 129±11 | 0.025 |
| Day DBP, mm Hg | 75 (68 to 77) | 77 (69 to 83) | 0.77 |
| Night SBP, mm Hg | 110±10 | 119±16 | 0.003* |
| Night DBP, mm Hg | 64±7 | 67±9 | 0.19 |
| ND systolic ratio | 0.88 (0.83 to 0.94) | 0.93 (0.86 to 0.99) | 0.07 |
| ND diastolic ratio | 0.82 (0.77 to 0.91) | 0.89 (0.82 to 0.95) | 0.05 |
| Ejection fraction, % | 64±7 | 66±11 | 0.27 |
| LVH | 9 (36) | 21 (77) | 0.001* |
| Impaired relaxation | 2 (8) | 5 (20) | 0.01* |
| Diastolic dysfunction | 0 (0) | 6 (24) | |
| Smoker | 1 (4) | 15 (17) | 0.11 |
| Heart failure | 0 (0) | 12 (13) | 0.05 |
| CAD | 0 (0) | 18 (20) | 0.01* |
| AF | 0 (0) | 9 ((10) | 0.09 |
| ACS | 0 (0) | 6 (7) | 0.18 |
| Stroke | 0 (0) | 6 (7) | 0.18 |
| DM | 0 (0) | 23 (26) | 0.007* |
| Insulin treatment | 0 (0) | 15 (17) | 0.03 |
| IFG | 5 (20) | 46 (51) | 0.04 |
Data are presented as mean ± SD, median (Q1–Q3), or number (percentage of population).
ACS, acute coronary syndrome; AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CRP, C-reactive protein; DM, diabetes mellitus; DPB, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IFG, impaired fasting glycemia; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; ND, night-day; NtoL, neutrophil to lymphocyte ratio; SBP, systolic blood pressure; TG, triglycerides; TC, total cholesterol; WBC, white blood cells.
p values significant after controlling for false discovery rate at a level of 0.05 according to the Benjamini-Hochberg procedure.